BridgeBio Oncology Therapeutics, Inc. — Insider Transactions
Form 4 filings by directors, officers, and 10%+ shareholders
SEC rules require corporate insiders — including directors, executive officers, and any shareholder owning more than 10% of a company's shares — to report changes in their ownership within two business days of a transaction. These disclosures are filed as Form 4. Open-market purchases (code P) are generally considered the most meaningful signal, as insiders are spending their own money.
| Insider | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| BridgeBio Pharma, Inc. | — | Other | 784,720 | — | — | Oct 10, 2025 |
| Chen Bihua | — | Award / Grant | 639,110 | $10.72 | $6,851,259 | Aug 11, 2025 |
| Holman Albert A III | — | Option Exercise | 30,000 | — | — | Aug 11, 2025 |
| McKenna Mark C. | — | Option Exercise | 30,000 | — | — | Aug 11, 2025 |
| Schmid John P. | — | Option Exercise | 30,000 | — | — | Aug 11, 2025 |
| Chen Bihua | CEO and Chairperson | Purchase | 903,600 | $10.00 | $9,036,000 | Feb 13, 2024 |
| Helix Holdings II LLC | — | Award / Grant | 509,000 | $10.00 | $5,090,000 | Feb 13, 2024 |